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Summary
Background: An association between stress and autoimmune thyroid disease (AITD) (especially
Graves’ hyperthyroidism) has been reported, but all studies so far on this topic have been
retrospective.
Objective: To evaluate prospectively the relationship between stress and (i) de novo occurrence of
thyroid antibodies and (ii) development of overt autoimmune hyper-/hypothyroidism.
Study design: Two nested case—control studies in a prospective cohort of 790 euthyroid women who
were 1st or 2nd degree relatives of AITD patients. Follow-up was five year, with annual assessments
including questionnaires on stressful life events, daily hassles, and mood. In study A, cases were
subjects who developed TPO-Ab but remained euthyroid during follow-up (called event). In study B,
cases were subjects who developed overt hypothyroidism (TSH > 5.7 mU/l and FT4 < 9.3 pmol/l) or
overt hyperthyroidism (TSH < 0.4 mU/l and FT4 > 20.1 pmol/l) during follow-up (called event). For
each case, two controls were selected, matched for age and duration of follow-up; controls in study
A remained TPO-Ab negative, and in study B remained without overt hyper-/hypothyroidism.
Outcomes: Contrast in questionnaire responses between cases and controls at baseline, at one year
prior to the event and at time of event.
Results: Exposure to stress was not different between subjects who developed or did not develop
TPO-Ab (study A). No differences were observed in stress questionnaires between hyper-/hypothy-
roid cases and controls at any time point, but hypothyroid cases had less negative feelings than
controls at the time of diagnosis (study B).
Conclusion: The data suggest that stress is not involved in the pathogenesis of AITD.
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1192 G. Effraimidis et al.1. Introduction
Autoimmune thyroid disease (AITD) results from a complex
interplay among genetic and environmental factors. Evi-
dence for a genetic base of this disease is strong as siblings
and other family members of AITD patients are at increased
risk for AITD (Chopra et al., 1977; Jacobson and Tomer, 2007).
The sibling recurrence risk ratio (ls) is 11.6 for Graves’ and
28.0 for Hashimoto’s disease (Villanueva et al., 2003). In
women with at least one first degree relative with AITD, the
incidence of Graves’ hyperthyroidism is 4.1—4.3 times higher
and of Hashimoto’s hypothyroidism 1.9—2.7 times higher
than the general female population (Strieder, 2008). Twin
studies suggest that genetic factors play a major role,
accounting for about 70% of the risk to get AITD (Brix
et al., 2000, 2001; Tomer and Huber, 2009). The remaining
30% must be due to environmental factors, which alter the
immune reaction depending on the duration and intensity of
exposure (Prummel et al., 2004). Among those factors is
stress.
Stress affects the immune system both directly and indir-
ectly through the activation of neural and endocrine systems
(Chrousos, 1998; Elenkov, 2004). The phenotypic expression
of AITD is to a large extent dependent on the balance of Th1
versus Th2 immune response (Weetman, 2004). During per-
iods of stress an increase of the secretion of glucocorticoids
and catecholamines is observed as a result of the activation
of the sympathoadrenal system and the hypothalamic—pitui-
tary—adrenal axis, respectively. Both glucocorticoids and
catecholamines cause a selective suppression of Th1
response and a shift toward Th2 mediated humoral immunity
(Chrousos and Elenkov, 2006). This mechanism may promote
the development of Graves’ disease, which is a Th2 predo-
minant disease (Tsatsoulis, 2006). On the other hand, a
hypoactive hypothalamic—pituitary—adrenal axis may leads
to a predominantly Th1-mediated immune activity (Wilder,
1995), which may promote thyroid cell destruction and
Hashimoto’s thyroiditis through apoptotic pathways on thyr-
oid follicular cells.
The natural history of AITD probably starts with a parti-
cular genetic background and then several stages can be
distinguished. The first stage in the natural history of thyroid
autoimmunity that can be detected is the occurrence of TPO-
Ab. Thereafter, changes in serum TSH at values outside the
normal range follow (subclinical hypo- or hyperthyroidism)
and the disease ends in many instances with overt hypo- or
hyperthyroidism. In order to get more insight in the influence
of stress on the natural course of AITD we did two nested
case—control studies within the Amsterdam AITD cohort. The
aim of the first study was to evaluate the relationship
between stress and the de novo occurrence of TPO-Ab and
the aim of the second study was to evaluate the relationship
between stress and the development of overt hypothyroidism
or overt hyperthyroidism.
2. Subjects and methods
2.1. Participants
The present study was carried out among the 803 subjects
from the Amsterdam AITD Cohort. The original cohort haspreviously been described in detail (Strieder et al., 2003). In
short, the cohort consisted of women between 18 and 65
years of age in self proclaimed good health without a history
of thyroid disease, who had at least one 1st or 2nd degree
relative with documented autoimmune hyper- or hypothyr-
oidism. Subjects were followed for five years, or shorter
when overt hyper- or hypothyroidism had occurred (defined
as TSH < 0.4 mU/l in combination with FT4 > 20.1 pmol/l, or
TSH > 5.7 mU/l in combination with FT4 < 9.3 pmol/l,
respectively). At each annual visit blood samples were col-
lected to measure TSH, FT4, T3, TPO-Ab, Tg-Ab and TBII, and
subjects were asked to fill a number of questionnaires on
stressful life events, daily hassles, and mood.
The Dutch questionnaire on Recent Experienced Stressful
Life Events (van de Willige et al., 1985; Brosschot et al.,
1994) counts the total number of major life events experi-
enced in the last 12 months (checklist of 60 possible events).
The respondent scores separately the amount of pleasantness
and unpleasantness with each experienced life event, rated
on a scale of zero (meaning no (un)pleasantness at all) to four
(a huge amount of (un)pleasantness). From this scale, the
total amount of pleasantness and unpleasantness is calcu-
lated (maximum score 240 for each). When the amount of
pleasantness exceeds the amount of unpleasantness the
event is categorized as being pleasant and vice versa, yield-
ing the total number of (un)pleasant events (maximum 60).
The Dutch Everyday Problem Checklist, a validated version of
the daily hassles scale (Kanner et al., 1981; Vingerhoets
et al., 1989, 1996), consists of 114 items concerning daily
hassles in the last two months. It also measures the intensity
of each hassle on a scale from zero to three, yielding the
number of hassles experienced and the total intensity of
these hassles (maximum 342). The Positive and Negative
Affect Schedule (PANAS, Watson et al., 1988) measures the
current mood, in terms of positive and negative affect. It
consists of 22 mood states (11 positive, 11 negative) and the
respondent is asked to report whether she is affected by each
of these states on a scale from 1 (not at all) to 5 (a lot). This
yields the tendency to report positive and negative affect
states both on a scale from 11 to 55.
Results of thyroid function tests at study entrance
revealed overt hypothyroidism in 10 subjects and overt
hyperthyroidism in 3 subjects, leaving 790 subjects to be
included in the present study. Within this cohort we per-
formed two nested case—control studies. In both studies, for
each case two controls were selected. Controls were
matched by age and duration of follow-up. Matching by
age was done in view of the increase in prevalence of thyroid
antibodies with advancing age (Hollowell et al., 2002). A
subject could only be sampled once as control. From all
possible subjects who could serve as candidate controls,
we selected those that were closest to the corresponding
case, first for age and then for the follow-up period.
Study A. In order to evaluate the relationship between
stress and the de novo occurrence of TPO-Ab, we selected
participants from the original cohort as follows (Fig. 1): from
the 790 euthyroid at study entrance subjects, we excluded
those who had thyroid antibodies (i.e. serum concentrations
of either TPO-Ab of 100 kU/l or greater, Tg-Ab of 100 kU/l or
greater, or TBII of 12 U/l or greater). From the remaining 549
euthyroid subjects without thyroid antibodies we subse-
quently excluded those who had subclinical hyper- or
Figure 1 Flowchart of the recruitment of subjects for study A.
Involvement of stress in AITD 1193hypothyroidism (abnormal TSH in the presence of normal FT4
and T3) and those who had no follow-up. Five hundred
twenty-one euthyroid participants without any serological
sign of AITD at baseline were thus enrolled. In this study, a
subject was recruited as a case when she remained euthyroid
but had developed TPO-Ab. The end-point for a case was the
time at which she had become positive for the first time for
TPO-Ab without developing abnormal TSH (called event).
Controls should have remained euthyroid and seronegative
for TPO-Ab up to the time at which the case they were
matched to, had received her end-point.
Study B. In order to evaluate the relationship between
stress and the development of overt hypothyroidism or overt
hyperthyroidism, we designed a nested case—control study
among the 790 subjects euthyroid at study entrance. A
subject was recruited as a case when she had developed
over hypothyroidism or overt hyperthyroidism during follow-
up (called event). The end-point for a case was the time at
which she had developed overt hypo- or hyperthyroidism.
Controls should have normal TSH up to the time at which the
case they were matched to, had received her end-point.
Stress measurements at baseline, in the year prior to and
at the time of the seroconversion to TPO-Ab for study A and
the development of overt hypo- or hyper-thyroidism for study
B were compared between cases and controls.
2.2. Laboratory measurements
Serum TSH and FT4 were measured using time-resolved
fluoroimmunoassay (Delphia, Turku, Finland). Reference
values are for TSH 0.4—5.7 mU/l and for FT4 9.3—
20.1 pmol/l. Thyroid peroxidase (TPO) antibodies and thyr-
oglobulin (Tg) antibodies were measured by chemilumines-
cence immunoassays (LUMI-test anti-TPO and LUMI-test anti-
Tg, respectively, Brahms, Berlin, Germany). Improved ver-
sions of both assays became available during follow-up:detection limits of these new assays were for TPO-Ab
30 kU/l and for Tg-Ab 20 kU/l. TPO-Ab concentrations
obtained with the old assay were multiplied by a factor
0.72 to obtain comparative values in the new assay. TPO-
Ab and Tg-Ab concentrations were considered to be positive
at values 100 kU/l. TSH receptor antibodies were deter-
mined as TSH binding inhibitory immunoglobulins (TBII) using
the TRAK assay (Brahms, Berlin, Germany); detection limits
in the 1st and 2nd generation TRAK assays were 5 and 1 IU/l,
respectively, and values above 12 and 1.5 U/l, respectively
were considered as positive.
3. Statistical analysis
Values are given as mean  SD for age and follow-up period
but as median and interquartile range for TSH and TPO-Ab.
Differences between cases and controls were evaluated by
Mann—Whitney U-test for stress parameters. A p-value of
<0.05 was considered to indicate significant differences
between groups.
4. Results
4.1. Study A. Stress and development of TPO-Ab
During the 5-year follow-up period, 81 of the 521 subjects
(15.5%) had developed TPO-Ab while their TSH remained
normal (Table 1). The mean age of the converters to TPO-
Ab was 36  12 years and the mean follow-up was 2.8  1.3
years. Controls mean age and mean follow-up did not differ
from cases. At the time of seroconversion the TPO-Ab con-
centration had a median value of 140 kU/l (interquartile
range 110—160 kU/l). Statistical analysis at baseline, at time
one year prior the occurrence of event and at time of event
revealed no significant differences or trends in reported
stress between cases and controls with respect to any of
the questionnaires (Table 2). The results for developing
either TPO-Ab and/or Tg-Ab were essentially the same
(see the table in the supplementary data on the journal
website).
4.2. Study B. Stress and development of overt
hypo- or hyperthyroidism
During the 5-year follow-up period 13 cases of overt auto-
immune hyperthyroidism and 38 cases of overt autoimmune
hypothyroidism occurred after a mean follow-up of 2.7  1.5
and 3.2  1.3, respectively (Table 1). The cause of overt
hyperthyroidism was Graves disease in 11 subjects (1 had
Graves ophthalmopathy), postpartum thyroiditis in 1 sub-
ject, and silent thyroiditis in 1 subject. All subjects with
overt hyperthyroidism had positive TPO-Ab and/or Tg-Ab at
the time of diagnosis; TSH receptor antibodies were absent in
the two patients diagnosed with postpartum thyroiditis and
silent thyroiditis, but present in 6 out of 7 patients diagnosed
with Graves’ hyperthyroidism (TBII was not measured in the
time of diagnosis in 4 Graves’ patients). TSH receptor anti-
bodies were undetectable in all controls at each time point,
and in all cases at baseline and at the year before the event.
Cases and controls did not differ with regard to mean age and
mean follow-up.
Table 1 Characteristics of subjects who developed TPO-Ab (study A) or overt autoimmune thyroid disease (study B) and their corresponding controls at time of study entrance and at
consecutive time points of follow-up, in a nested case—control study of women with 1st or 2nd degree relatives with proven AITD derived from the prospective Amsterdam AITD cohort.
N Age,
years (SD)
Follow-up,
years (SD)
TSH (mU/l) FT4 (pmol/l) TPO-Ab (kU/l) Tg-Ab (kU/l)
Baseline At time of
event
Baseline At time of
event
Baseline At time of
event
Baseline At time of
event
Study A
Cases 81 36 (12) 2.8 (1.3) 1.5 (1.2—2.2) 1.5 (1.1—2.2) 13.1 (11.6—14.5) 13.1 (11.9—14.5) <25 (<25—<25) 140 (110—160) 15 (<5—25) 17 (6—43)
Controls 162 36 (12) 2.8 (1.3) 1.5 (1.1—2.1) 1.4 (1.0—2.0) 13.1 (11.9—14.5) 13.1 (11.9—14.9) <25 (<25—<25) <25 (<25—50) 5 (<5—15) 6 (6—15)
p-Valuesa 0.95 0.17 0.79 0.99 0.89 <0.001 0.005 <0.001
Study B1 (hyperthyroidism)
Cases 13 41 (14) 2.7 (1.5) 1.6 (1.1—2.2) 0.02 (0.01—0.13) 13.3 (12.0—14.1) 41.5 (33.5—56.0) 560 (<25—1940) 1310 (50—3000) 38(23—108) 175 (44—185)
Controls 26 41 (14) 2.7 (1.5) 1.5 (1.2—2.2) 1.9 (1.2—2.6) 14.1 (12.0—15.7) 13.0 (12.2—14.1) <25 (<25—80) 40 (<25—50) 17 (<5—41) 26 (<5—115)
p-Valuesa 0.85 0.34 <0.001 <0.001 0.01 0.03 <0.001
Study B2 (hypothyroidism)
Cases 38 38 (12) 3.2 (1.3) 4.2 (2.7—5.7) 14.8 (6.3—16.9) 10.7 (9.7—11.6) 7.1 (4.8—8.4) 1123 (304—2239) 3000 (1620—6670) 75 (40—238) 140 (100—500)
Controls 76 38 (12) 3.2 (1.2) 1.6 (1.1—2.5) 1.4 (1.0—2.1) 12.8 (11.3—14.5) 13.0 (11.8—15.1) 25 (<25—50) 25 (<25—170) 8 (<5—29) 11 (6—69)
p-Valuesa <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Data are given as mean  SD or median with interquartile range. Time of event: first occurrence of TPO-Ab (study A), or diagnosis of hyper- or hypothyroidism (study B). TSH: thyroid stimulating
hormone, FT4: free T4, TPO: thyroid peroxidase, Tg: thyroglobulin.
a Cases versus controls.
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Table 2 Comparison of scores on three questionnaires (recent experienced life events, daily hassles, PANAS) between patients who developed TPO-Ab and remained euthyroid
(normal TSH) and their corresponding controls matched for age and follow-up, in a nested case—control study of 243 women with 1st or 2nd degree relatives with proven AITD derived
from the prospective Amsterdam AITD cohort.
Baseline One year before event At event p-Value
Cases Controls Cases Controls Cases Controls Baseline One year
before event
At event
Positive and negative affect schedule scale (tendency to report)
Positive feelings 39.0 (35.0—42.0) 38.0 (34.0—42.0) 38.0 (35.0—41.0) 38.0 (34.0—41.0) 37.0 (34.0—41.0) 37.0 (34.0—41.0) 0.598 0.244 0.499
Negative feelings 22.0 (17.0—28.0) 21.0 (16.0—28.0) 21.0 (16.0—26.0) 22.00 (15.0—27.0) 20.0 (16.0—27.0) 20.00 (15.0—27.0) 0.483 0.622 0.532
Recent life events
Total number 10.0 (7.0—15.0) 11.0 (7.0—15.0) 9.0 (5.0—15.0) 9.0 (6.0—14.0) 8.0 (5.0—13.0) 9.0 (5.0—13.0) 0.381 0.607 0.361
Number of unpleasant
life events
5.0 (3.0—7.0) 5.0 (3.0—7.0) 4.0 (2.0—6.1) 3.0 (2.0—6.0) 3.0 (1.0—6.0) 3.0 (2.0—6.0) 0.577 0.488 0.640
Number of pleasant
life events
5.0 (3.0—6.0) 4.0 (3.0—7.0) 4.0 (2.0—7.0) 4.0 (2.0—6.0) 3.0 (1.0—5.0) 4.0 (2.0—6.0) 0.756 0.730 0.357
Amount of total
unpleasantness
15.0 (7.0—23.0) 17.0 (9.0—25.0) 12.0 (6.0—23.39) 12.0 (7.0—21.0) 12.0 (5.0—20.1) 13.0 (6.0—21.0) 0.387 0.915 0.634
Amount of total
pleasantness
16.0 (9.0—23.0) 16.0 (9.15—24.0) 15.0 (7.0—24.0) 13.0 (8.0—22.0) 13.0 (6.0—20.0) 13.0 (6.0—21.0) 0.596 0.672 0.573
Daily hassles
Total number of
daily hassles
22.0 (17.0—35.0) 23.0 (14.0—35.0) 25.5 (15.5—37.5) 22.0 (15.0—35.0) 25.5 (14.0—36.0) 23.0 (14.0—36.0) 0.595 0.328 0.621
Intensity per hassle 1.36 (1.12—1.78) 1.32 (1.0—1.56) 1.40 (1.11—1.78) 1.33 (1.0—1.61) 1.35 (1.03—1.62) 1.33 (1.07—1.65) 0.069 0.089 0.679
Total intensity of
all hassles
30.0 (20.0—52.0) 29.0 (15.1—50.0) 33.0 (20.0—55.5) 30.0 (14.0—51.0) 33.0 (18.0—54.0) 29.0 (16.0—51.0) 0.222 0.097 0.419
Data are given as median with interquartile range between parentheses. p-Value of cases versus controls. Time of event: visit when diagnosis of overt hyper- or hypothyroidism was made or
confirmed. PANAS: positive and negative affect schedule.
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Table 3 Comparison of scores on three stress questionnaires (recent experienced life events, daily hassles, PANAS) between patients who developed overt auto-immune thyroid
disease (AITD) and their corresponding controls matched for age and follow-up.
Baseline One year before event At event p-Value
Cases Controls Cases Controls Cases Controls Baseline One year
before event
At
event
Hyperthyroism study B1
Positive and negative affect schedule scale (tendency to report)
Positive feelings 39.0 (38.0—41.0) 38.0 (35.0—39.0) 36.0 (34.0—40.0) 37.0 (34.0—40.0) 36.0 (30.5—41.5) 37.0 (34.0—39.0) 0.05 0.70 0.93
Negative feelings 22.0 (19.0—26.0) 19.0 (15.0—29.0) 20.0 (15.0—22.0) 19.0 (15.0—26.0) 19.0 (15.0—25.0) 18.0 (13.0—22.0) 0.48 0.64 0.72
Recent life events
Total number 7.0 (7.0—9.0) 9.5 (6.0—14.0) 7.0 (4.0—9.0) 7.0 (5.0—13.0) 9.0 (2.0—11.0) 9.0 (7.0—12.0) 0.64 0.54 0.33
Number of unpleasant
life events
4.0 (2.0—4.0) 5.0 (3.0—7.0) 4.0 (2.0—7.0) 5.0 (1.0—7.0) 2.0 (0.0—6.0) 5.5 (3.0—7.0) 0.36 0.84 0.17
Number of pleasant life events 3.0 (3.0—5.0) 4.5 (2.0—9.0) 2.0 (1.0—5.0) 3.0 (2.0—4.0) 2.0 (1.0—6.0) 3.0 (2.0—5.0) 0.69 0.60 0.86
Amount of total
unpleasantness
11.0 (9.0—16.0) 15.6 (6.0—20.0) 11.0 (8.0—13.0) 14.0 (5.0—21.0) 6.0 (1.0—22.0) 17.0 (8.0—24.0) 0.89 0.74 0.22
Amount of total pleasantness 14.0 (9.0—18.0) 15.0 (6.0—21.0) 7.0 (5.0—17.0) 9.0 (5.0—16.0) 8.0 (2.0—20.0) 12.0 (7.1—16.0) 0.85 0.99 0.78
Daily hassles
Total number of daily hassles 24.0 (14.0—26.0) 22.5 (14.0—32.0) 21.0 (15.0—26.5) 20.0 (16.0—37.0) 16.0 (12.0—18.0) 24.0 (12.0—37.0) 0.57 0.59 0.33
Intensity per hassle 1.5 (1.4—1.8) 1.3 (0.9—1.7) 1.5 (1.4—1.6) 1.4 (0.9—1.7) 1.2 (1.1—1.6) 1.4 (1.1—1.7) 0.08 0.52 0.92
Total intensity of all hassles 29.0 (14.0—50.0) 29.0 (12.0—43.0) 31.5 (20.1—42.0) 29.0 (20.0—56.0) 19.0 (14.0—32.0) 32.5 (17.0—52.0) 0.77 0.87 0.38
Hypothyroism study B2
Positive and negative affect schedule scale (tendency to report)
Positive feelings 39.0 (36.0—43.0) 38.0 (35.0—41.0) 35.0 (31.0—40.0) 39.0 (34.0—42.0) 37.0 (34.0—41.0) 38.0 (32.0—42.0) 0.21 0.10 0.92
Negative feelings 21.5 (19.0—27.0) 23.0 (18.5—28.5) 20.0 (15.0—26.0) 22.0 (17.0—26.5) 17.0 (14.0—21.0) 23.0 (16.0—28.5) 0.51 0.40 0.01
Recent life events
Total number 7.5 (4.0—15.0) 10.5 (6.0—14.5) 8.5 (4.0—12.0) 8.0 (6.0—11.0) 9.0 (6.0—12.0) 7.5 (4.5—12.5) 0.13 0.66 0.23
Number of unpleasant
life events
2.0 (1.0—6.0) 4.0 (2.0—6.0) 3.0 (2.0—6.1) 4.0 (1.5—5.5) 3.0 (1.0—5.0) 3.0 (1.0—5.0) 0.17 0.68 0.97
Number of pleasant life events 3.0 (1.0—6.0) 4.0 (3.0—6.5) 3.0 (1.0—6.0) 3.5 (2.0—6.0) 5.1 (3.0—7.0) 3.5 (2.0—5.0) 0.11 0.52 0.05
Amount of total unpleasantness 8.0 (3.0—19.2) 13.5 (8.0—21.5) 10.0 (4.0—20.2) 12.0 (7.5—19.5) 9.0 (4.0—17.7) 10.5 (5.0—18.0) 0.04 0.30 0.70
Amount of total pleasantness 12.5 (5.0—25.0) 14.5 (11.0—25.0) 11.5 (4.0—22.0) 13.0 (8.0—21.0) 16.7 (12.0—23.5) 11.5 (7.0—20.0) 0.13 0.43 0.05
Daily hassles
Total number of daily hassles 18.0 (16.0—28.0) 23.5 (17.0—33.0) 20.0 (13.0—29.0) 23.0 (16.0—32.0) 19.5 (12.0—33.0) 22.5 (14.0—34.0) 0.09 0.24 0.54
Intensity per hassle 1.2 (1.0—1.4) 1.3 (1.0—1.6) 1.4 (1.1—1.7) 1.3 (1.0—1.7) 1.2 (1.0—1.6) 1.4 (1.1—1.6) 0.35 0.47 0.35
Total intensity of all hassles 23.0 (15.0—34.0) 27.0 (18.5—46.0) 24.0 (16.0—47.0) 28.0 (19.0—44.0) 24.5 (11.0—41.5) 28.0 (17.0—51.0) 0.10 0.78 0.34
Data are given as median with interquartile range between parentheses. p-Value of cases versus controls. Time of event: visit when diagnosis of overt hyper- or hypothyroidism was made or
confirmed. PANAS: positive and negative affect schedule.
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Involvement of stress in AITD 1197We observed no differences in any of the three stress
questionnaires between hyperthyroid cases and controls at
baseline, at time one year before occurrence of the event
and at time of the occurrence of the event (Table 3).
At study entrance and at the year prior the event, we did
not find any differences between hypothyroid cases and
controls in recent life events, daily hassles, or affect scales
(Table 3) except a lower amount of total unpleasantness in
the hypothyroid cases than in controls at baseline. At the
time of event, hypothyroid cases compared to controls
reported significantly less frequently negative feelings at
the time when diagnosis was made than controls. No other
significant differences were found.
We also tested if AITD was more prevalent in subjects who
were exposed to severe stress and for that reason we ana-
lyzed the data in order to uncover possible differences in the
extreme ends of any of the stress measurements for both
study A and study B. We found that the proportion of subjects
in whom measurements were above the 80th percentile did
not differ between cases and controls. When we used the
quadratics of the stress measurements, the results did not
change either.
5. Discussion
The aim of our case—control studies nested in the observa-
tional Amsterdam AITD cohort study (Strieder et al., 2008)
was to evaluate in a prospective manner the involvement of
stress in both the early stages (when thyroid antibodies
develop but thyroid function is still normal) and late stages
(when overt thyroid dysfunction emerges) of the natural
course of AITD. The observed differences between cases
and controls in both studies were either nonexistent or of
marginal significance at study entrance and during follow-up,
with the exception of a lower frequency of negative feelings
reported at the time of the occurrence of hypothyroidism.
The thyroid autoimmune process takes years (Effraimidis
et al., 2011), resulting in many cases in overt autoimmune
hypo- or hyperthyroidism. All studies in the past on the
relationship of stress and overt autoimmune hypo- or
hyperthyroidism, measured stress by questionnaires at the
time of the diagnosis. This approach raises the question of
distinguishing between cause and effect, as the diseases
themselves might generate stress in a patient. If stress would
play a provocative role in the early stages of AITD, one would
expect an association of stress and the occurrence of TPO-Ab,
as the occurrence of TPO-Ab is one of the earliest events in
AITD. Our results do not indicate such an association. These
findings are in an agreement with our previous longitudinal
cross sectional study (Strieder et al., 2005) in which no
association was found between stressful life events, daily
hassles and mood and the presence of anti-TPO antibodies in
euthyroid women.
We observed no increase in stress between hypothyroid
cases and controls at baseline, in the year preceding the event
or at the time of event in recently life events and daily hassles.
Only two papers in the past reported on the association
between stress and autoimmune hypothyroidism. Both papers
failed to find any association between stress and autoimmune
hypothyroidism. In one study (Martin-du Pan, 1998) the trigger-
ing role of stress was assessed in 95 patients with Hashimoto’sthyroiditis and 97 patients with benign thyroid nodules used as
controls. Stress did not have any triggering role in Hashimoto’s
thyroiditis. Another study (Oretti et al., 2003) evaluated the
association between stress and the occurrence of postpartum
thyroiditis. There was no excess of life events in women who
developed postpartum thyroiditis with no difference in the
number of life events between antibody positive and antibody
negative women. In agreement with these studies, our study
also did not observe any differences between hypothyroid
cases and controls. We only observed significant difference
between hypothyroid cases and their respective controls on the
PANAS negative affect scale, indicating a lower tendency to
report negative feelings in cases at the time of event. If
anything, we observed effects in the direction opposite to
our expectation: we found that that hypothyroid cases, com-
pared to their respective controls scored higher at the time of
diagnosis on the PANAS negative affect scale, indicating a lower
tendency to report negative feelings in cases. Moreover we
found that at the time of diagnosis they also reported to have
experienced more pleasant events and a higher total pleasant-
ness of these events in the preceding 12 months.
We also did not detect any causal relationship between
stressful life events and Graves’ hyperthyroidism. Our find-
ings are in contrast with several case—control studies in the
past which have reported on a positive relationship between
stress and the development of Graves’ hyperthyroidism (Cho-
pra et al., 1977; Winsa et al., 1991; Sonino et al., 1993; Kung,
1995; Chiovato and Pinchera, 1996; Radosavljevic´ et al.,
1996; Yoshiuchi et al., 1998; Dayan, 2001). All studies were
retrospective in nature and were influenced of recall bias as
Graves’ disease patients were asked to report on stressful life
events either at the time they were still hyperthyroid or even
later when euthyroidism was restored. Furthermore, it could
not be ruled out that negative, stressful life events in the
year preceding the onset of Graves’ hyperthyroidism were
not the cause but the consequence of thyrotoxicosis. This
issue was addressed to a certain extent in a study which
reported an increase in negative life events in Graves’ dis-
ease patients compared with non-autoimmune hyperthyroid
subjects (Matos-Santos et al., 2001).
A weakness of our study is the limited number of subjects
who converted from euthyroidism to overt hypothyroidism
(N = 38) or hyperthyroidism (N = 13). It should be pointed out
that cases in study B with thyroid antibodies at baseline are
already at substantial higher risk of developing overt hypo- or
hyperthyroidism, independently of stressful situations. A
larger number of cases and a longer follow-up period are
required to more accurately outline the role of stress. This
limitation is in our view well balanced by the strengths of our
study. Its prospective nature guarantees more solid evidence
than obtained from cross-sectional studies. Moreover, in the
nested case—control study a perfect match existed between
both groups with respect to age and duration of follow-up.
Higher age and longer exposure time both increase the like-
lihood of developing thyroid antibodies, constituting possible
bias. The matching procedure effectively excluded both bias.
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